Deferasirox treatment for myelodysplastic syndromes: "Real-life" efficacy and safety in a single-institution patient population

Annals of Hematology

Volumn 91, Issue 9, 2012, Pages 1345-1349

  Breccia, Massimo ^a   Finsinger, Paola ^a   Loglisci, Giuseppina ^a   Federico, Vincenzo ^a   Santopietro, Michelina ^a   Colafigli, Gioia ^a   Petrucci, Luigi ^a   Salaroli, Adriano ^a   Serrao, Alessandra ^a   Latagliata, Roberto ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Deferasirox; Efficacy; Erythroid response; MDS; Safety

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; LENALIDOMIDE;

5Q- SYNDROME; ADULT; AGED; ARTICLE; CATARACT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES; AZACITIDINE; BENZOIC ACIDS; CHELATING AGENTS; DRUG ERUPTIONS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATINICS; HUMANS; IRON OVERLOAD; KIDNEY DISEASES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84864955625     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1481-7     Document Type: Article

References (15)

1. Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872-1885
2. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 28:2847-2852
3. Kao JM, McMillan A, Greenberg PL (2008) International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765-770
4. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59
5. Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M (2011) Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96(10):1433-1440
6. Groenveld HF, Januzzi JL, Damman K, van Wjingaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients: a systematic review and metaanalysis. J Am Coll Cardiol 52:818-827
7. Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 3:S2-S6
8. Leitch HA (2010) Iron chelation therapy in MDS: does it improve survival? Leuk Res 34:852-853
9. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies) (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34:864-870
10. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci- Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators (2010) Deferasirox in iron-overload patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34:1143-1150
11. Porter JB (2009) Deferasirox: an update. Hemoglobin 1:S70-S75
12. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S, Italian Society of Hematology (2010) Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 34:1576-1588
13. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425
14. Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C (2010) Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 34:1560-1565
15. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Marcellari A, Roubert B, Rose C (2012) Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica. doi:10.3324/haematol.2011.048546